Prostate cancer is the most prevalent cancer in men worldwide. As new treatments become available, costs also increase, and patients from lower-middle-income countries do not have access to those ...
Hosted on MSN
'It’s like chemical castration': The devastating effect of hormone treatment for prostate cancer
On September 13, writer and broadcaster Manchán Magan was a guest on the RTÉ Radio’s Brendan O’Connor Show. Magan had a rare aggressive form of prostate cancer, and that Saturday morning, he revealed ...
CHICAGO -- Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received ...
Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome For men with CRPC, a castrate state should be maintained ...
Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...
New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients. The study in The ...
ODAC voted 7–1 (one abstention) that capivasertib plus abiraterone and ADT shows a favorable benefit–risk profile for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results